Key Trends and Insights into the Dermatological Drugs Market: Growth Rate and Opportunities to 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the dermatological drugs market grown over the years?
The market size of dermatological drugs has seen robust growth over recent years. It is projected to increase from $20.06 billion in 2024 to $22.04 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.8%. The historic growth phase can be traced back to an increasing number of skin disorders, advancements made in drug formulation and administration, heightened skincare and aesthetic consciousness, expanding senior population, and a rising demand for over-the-counter dermatological products.
What Is the forecasted market size and growth rate for the dermatological drugs market?
The market for dermatological drugs is predicted to witness substantial growth in the coming years, expected to reach $31.75 billion in 2029, experiencing a compound annual growth rate (CAGR) of 9.6%. Several factors contribute to this growth in the forecasted period such as advancements in biologics and specific therapies, a surge in the adoption of virtual dermatology and digital health, a rise in skin conditions caused by lifestyle, escalated demand for personalized medicines and regeneration, and expanded research in therapies based on skin microbiome. Noteworthy trends expected during the forecast period encompass drug delivery through nanotechnology, dermatological diagnostics powered by AI, therapies focused on microbiome, skin regeneration through 3d bioprinting, and treatments centered on gene editing and RNA.
Get your dermatological drugs market report here!
https://www.thebusinessresearchcompany.com/report/dermatological-drugs-global-market-report
What are the major factors driving growth in the dermatological drugs market?
The expansion of the dermatological drugs market is anticipated to be powered by the proliferating demand for cosmetic dermatology operations. Focusing on enhancing looks through various non-operative procedures and treatments, cosmetic dermatology has grown to be a specialized niche within dermatology. The push for cosmetic dermatology is influenced by heightened consumer consciousness of aesthetic treatments, advancements in skincare technology, and a surge in favoritism towards non-invasive procedures designed to approve appearance and battle aging. An escalating demand for skin rejuvenation and anti-aging procedures under cosmetic dermatology is stimulating the progression of innovative dermatological drugs that propose secure, efficient, and barely invasive resolutions. To exemplify, the International Society of Aesthetic Plastic Surgery, a US-based professional entity, reported in January 2023 that over 12.8 million surgical and 17.5 million non-surgical operations were administered worldwide, accounting for a 19.3% ascend in total procedures from the prior reporting period. Furthermore, over 14.9 million surgical and 18.8million non-surgical operations will be performed globally in 2022, marking an 11.2% increase in total procedures executed. Consequently, the burgeoning operations in cosmetic dermatology are fueling the expansion of the dermatological drugs market.
What key areas define the segmentation of the global dermatological drugs Market?
The dermatological drugs market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Other Drug Classes
2) By Administration: Topical Administration, Oral Administration, Parenteral Administration
3) By Indication: Acne, Psoriasis, Rosacea, Alopecia, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Retinoids: Topical Retinoids, Oral Retinoids
3) By Antibiotics: Topical Antibiotics, Oral Antibiotics
4) By Antifungals: Topical Antifungals, Oral Antifungals
5) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors, Systemic Calcineurin Inhibitors
6) By Other Drug Classes: Biologics, JAK Inhibitors, Antihistamines, Photodynamic Therapy Agents
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21166&type=smp
What are the top market players propelling the growth of the dermatological drugs industry?
Major companies operating in the dermatological drugs market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Bausch Health Companies Inc., Organon International, Galderma, Incyte Corporation, Glenmark Pharmaceuticals Ltd., Mayne Pharma Group Limited, Dermavant Sciences Inc., Taro Pharmaceutical Industries Ltd., Biofrontera AG, Almirall SA, UCB SA, LEO Pharma A/S, Dermira Inc.
What are the key trends shaping the future of the dermatological drugs market?
The primary focus of large corporations involved in the dermatological drugs market is on the invention of biologic treatments to tackle long-standing skin issues like psoriasis, atopic dermatitis, and hidradenitis suppurativa. Biologics are designed to focus on distinct immune pathways, providing enhanced and durable respite compared to conventional treatments. For example, in September 2024, the US-based pharmaceutical firm, Eli Lilly and Company, gained authorization for Ebglyss (lebrikizumab), a specialized interleukin-13 (IL-13) inhibitor, for the management of moderate-to-severe atopic dermatitis in adults and children 12 years and older. This authorization signifies monumental progress by introducing a new biologic treatment method for patients who have not obtained sufficient symptom regulation with topical treatments. With a focus on presenting highly efficient treatments, Ebglyss intends to boost patients’ standard of living by alleviating severe pruritus and skin inflammation associated with moderate-to-severe atopic dermatitis.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21166
What regions are dominating the dermatological drugs market growth?
North America was the largest region in the dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatological drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Systemic Lupus Erythematosus Treatment Global Market Report 2025
Hematopoietic Stem Cell Transplantation Global Market Report 2025
Negative Pressure Wound Therapy Global Market Report 2025
https://thebusinessresearchcompany.com/report/negative-pressure-wound-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
